Evaluation of drug-induced QT prolongation in a halothane-anesthetized monkey model: Effects of sotalol

Journal of Pharmacological and Toxicological Methods

Volumn 59, Issue 2, 2009, Pages 86-93

  Ishizaka, Tomomichi ^a   Yoshimatsu, Yu ^a   Ozawa, Minori ^a   Kimotsuki, Tomofumi ^a   Takasaki, Wataru ^a   Manabe, Sunao ^a   Yasuda, Mitsuya ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Cynomolgus monkey; Halothane; Methods; Monophasic action potential; QT interval prolongation; Sotalol; Ventricular pacing

Indexed keywords

HALOTHANE; SOTALOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRADYCARDIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; EXPERIMENTAL MONKEY; FEMALE; HEART MUSCLE POTENTIAL; HEART MUSCLE REFRACTORY PERIOD; HEART PACING; HEART REPOLARIZATION; MALE; NONHUMAN; QT INTERVAL; QT PROLONGATION;

ACTION POTENTIALS; ANESTHETICS, INHALATION; ANIMALS; ANTI-ARRHYTHMIA AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ELECTROPHYSIOLOGY; FEMALE; HALOTHANE; HEART RATE; LONG QT SYNDROME; MACACA FASCICULARIS; MALE; MODELS, ANIMAL; SENSITIVITY AND SPECIFICITY; SOTALOL;

ANIMALIA; MACACA FASCICULARIS;

EID: 63749098224     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2009.01.002     Document Type: Article

References (24)

1. Anderson J.L., and Prystowsky E.N. Sotalol: An important new antiarrhythmic. American Heart Journal 137 (1999) 388-409
2. Barbey J.T., Sale M.E., Woosley R.L., Shi J., Melikian A.P., and Hinderling P.H. Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects. Clinical Pharmacology and Therapeutics 66 (1999) 91-99
3. Bazett H.C. An analysis of the time-relations of electrocardiogram. Heart 7 (1920) 353-370
4. Belardinelli L., Antzelevitch C., and Vos M.A. Assessing predictors of drug-induced torsade de pointes. Trends in Pharmacological Sciences 24 (2003) 619-625
5. Chiba K., Sugiyama A., Hagiwara T., Takahashi S., Takasuna K., and Hashimoto K. In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome. European Journal of Pharmacology 486 (2004) 189-200
6. Davies L.A., Hopkins P.M., Boyett M.R., and Harrison S.M. Effects of halothane on the transient outward K(+) current in rat ventricular myocytes. British Journal of Pharmacology 131 (2000) 223-230
7. Fridericia L.S. Die Systolendauer in Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Medica Scandinavica 53 (1920) 469-486
8. ICH. Safety pharmacology studies for human pharmaceuticals: S7A. Federal register 66 (2001) 36791-36792
9. ICH. The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals: S7B. Federal register 70 (2005) 61133-61134
10. Ishizaka T., Takahara A., Iwasaki H., Mitsumori Y., Kise H., Nakamura Y., et al. Comparison of electropharmacological effects of bepridil and sotalol in halothane-anesthetized dogs. Circulation Journal 72 (2008) 1003-1011
11. Koga T., Kuwano K., Kito G., and Kanefuji K. Evaluation of QT interval using a linear model in individual cynomolgus monkeys. Journal of Pharmacological and Toxicological Methods 55 (2007) 248-253
12. Li J., and Correa A.M. Kinetic modulation of HERG potassium channels by the volatile anesthetic halothane. Anesthesiology 97 (2002) 921-930
13. Omata T., Kasai C., Hashimoto M., Hombo T., and Yamamoto K. QT PRODACT: Comparison of non-clinical studies for drug-induced delay in ventricular repolarization and their role in safety evaluation in humans. Journal of Pharmacological Sciences 99 (2005) 531-541
14. Rizza C., Valderrabano M., and Singh B.N. Recurrent torsades de pointes after sotalol therapy for symptomatic paroxysmal atrial fibrillation in a patient with end-stage renal disease. Journal of Cardiovascular Pharmacology and Therapeutics 4 (1999) 129-134
15. Roden D.M. Drug-induced prolongation of the QT interval. The New England Journal of Medicine 350 (2004) 1013-1022
16. Kr blockade: Comparison with urethane anesthesia. Journal of Pharmacological Sciences 99 (2005) 185-190
17. Satoh Y., Sugiyama A., Takahara A., Ando K., Wang K., Honsho S., et al. The antipsychotic and antiemetic drug prochlorperazine delays the ventricular repolarization of the in situ canine heart. Journal of Pharmacological Sciences 97 (2005) 101-106
18. Satoh Y., Sugiyama A., Tamura K., and Hashimoto K. Effects of a class III antiarrhythmic drug, dofetilide, on the in situ canine heart assessed by the simultaneous monitoring of hemodynamic and electrophysiological parameters. Japanese Journal of Pharmacology 81 (1999) 79-85
19. + current in guinea pig ventricular cells. Journal of Pharmacological Sciences 95 (2004) 363-373
20. Singh B.N., Singh S.N., Reda D.J., Tang X.C., Lopez B., Harris C.L., et al. Amiodarone versus sotalol for atrial fibrillation. The New England Journal of Medicine 352 (2005) 1861-1872
21. + current by halothane and isoflurane. Anesthesia and Analgesia 90 (2000) 824-833
22. Kr channel blocker sematilide on the relationship between ventricular repolarization, refractoriness and onset of torsades de pointes. Japanese Journal of Pharmacology 88 (2002) 414-421
23. Takahara A., Sugiyama A., and Hashimoto K. Reduction of repolarization reserve by halothane anaesthesia sensitizes the guinea-pig heart for drug-induced QT interval prolongation. British Journal of Pharmacology 146 (2005) 561-567
24. Kr blockade. European Journal of Pharmacology 507 (2005) 169-177